Success Metrics

Clinical Success Rate
87.9%

Based on 29 completed trials

Completion Rate
88%(29/33)
Active Trials
3(5%)
Results Posted
28%(8 trials)
Terminated
4(7%)

Phase Distribution

Ph phase_1
2
4%
Ph phase_3
7
13%
Ph phase_4
13
24%
Ph not_applicable
20
36%
Ph phase_2
11
20%

Phase Distribution

2

Early Stage

11

Mid Stage

20

Late Stage

Phase Distribution53 total trials
Phase 1Safety & dosage
2(3.8%)
Phase 2Efficacy & side effects
11(20.8%)
Phase 3Large-scale testing
7(13.2%)
Phase 4Post-market surveillance
13(24.5%)
N/ANon-phased studies
20(37.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.3%

29 of 38 finished

Non-Completion Rate

23.7%

9 ended early

Currently Active

3

trials recruiting

Total Trials

55

all time

Status Distribution
Active(7)
Completed(29)
Terminated(9)
Other(10)

Detailed Status

Completed29
unknown10
Withdrawn5
Terminated4
Not yet recruiting4
Recruiting3

Development Timeline

Analytics

Development Status

Total Trials
55
Active
3
Success Rate
87.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (3.8%)
Phase 211 (20.8%)
Phase 37 (13.2%)
Phase 413 (24.5%)
N/A20 (37.7%)

Trials by Status

recruiting35%
terminated47%
withdrawn59%
not_yet_recruiting47%
unknown1018%
completed2953%

Recent Activity

Clinical Trials (55)

Showing 20 of 55 trialsScroll for more
NCT07263308Phase 3

Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

Recruiting
NCT06667999Phase 4

The Intensive Care Platform Trial

Recruiting
NCT06091345Not Applicable

Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites

Completed
NCT07395141Phase 3

Albumin in Acute Variceal Bleeding

Not Yet Recruiting
NCT05867602Phase 2

High Dose Albumin in Refractory Ascites

Recruiting
NCT02219165Phase 2

Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study

Completed
NCT05953623Phase 1

Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke Patients

Completed
NCT05937048Not Applicable

Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D).

Completed
NCT07002827Not Applicable

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Not Yet Recruiting
NCT06654687Not Applicable

Transthoracic Echocardiographic Monitoring of Cardiac Output Effects of Colloid Preload and Crystalloid Coload During Cesarean Delivery Under Spinal Anesthesia

Completed
NCT03654001Phase 3

ALBumin Italian Outcome Septic Shock-BALANCED Trial (ALBIOSS-BALANCED)

Completed
NCT06809088Not Applicable

Comparison of Safety and Efficacy of Tailored Versus Fixed Dose Albumin for the Management of Patients With Cirrhosis and Sepsis Associated Acute Kidney Injury

Not Yet Recruiting
NCT03919773Phase 1

IVIG (Gamunex-C) Treatment Study for POTS Subjects

Completed
NCT06245590Not Applicable

Evaluation of Low-dose Albumin and Midodrine Versus Midodrine Alone in Outcome of Recurrent Ascites in Patients With Decompensated Cirrhosis.

Unknown
NCT04416282Not Applicable

Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.

Completed
NCT04450654Phase 2

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

Withdrawn
NCT04109144Phase 2

Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis

Withdrawn
NCT05463471Phase 4

Effect of Balanced Saline Solution and Albumin on Volume Expansion in Shock Patients

Not Yet Recruiting
NCT04437810Not Applicable

To Study Efficacy of Albumin in Cirrhosis With Spontaneous Bacterial Peritonitis at Low Risk for AKI Development

Unknown
NCT04928859

Study on Efficacy and Safety of Human Albumin in Burn Shock Recovery

Completed

Drug Details

Intervention Type
DRUG
Total Trials
55